Milton Park companies transforming healthcare
Published on 30 April 2024
From milestones in patient care, promising financial outlooks and treatment data, growth and discoveries continue to progress at Milton Park.
Isansys and XRP Healthcare partnership to improve healthcare in Africa
Park-based Isansys, a global provider of advanced patient monitoring solutions, has announced its new partnership with XRP Healthcare.
This partnership will introduce Isansys’s state-of-the-art monitoring systems to pharmacies, hospitals and medical centres to be acquired by XRP Healthcare this year, improving healthcare infrastructure and services across Central Africa, starting in Uganda.
Keith Errey, CEO of Isansys, said: “We are excited to partner with XRP Healthcare to bring our cutting-edge patient monitoring solutions to Africa.
“This collaboration will not only benefit patients by ensuring better care and outcomes but also help healthcare providers deliver services more efficiently. We look forward to working together to elevate healthcare standards across the country.”
Exscientia outlines positive financials
Occupier Exscientia, a full stack AI drug discovery company, has shared its financial results for the fourth quarter and full year 2023, showcasing a positive outlook to move forward in its work.
Dr David Hallett, interim CEO and CSO at Exscientia, said: “In 2023, we significantly expanded our technological capabilities with the opening of our automation facility, concentrated our internal research on high value oncology targets and steadily progressed multiple new and existing programmes with our large pharma partners.
“We look forward to advancing our partnered programmes through potential milestones, while simultaneously linking new partnerships and expanding our technological capabilities.”
Promising data for Summit Therapeutics
Summit Therapeutics, based at Milton Park, has announced promising results for its novel, potential first-in-class investigational bispecific antibody, ivonescimab.
Whether used with chemotherapy or alone, both cohorts of patients experienced an intracranial response rate of 34%, with 23% experiencing a complete response by RANO criteria.
All patients who did not achieve a response demonstrated stable disease or non-progression.
Dr H. Jack West, Vice President of Clinical Development for Summit Therapeutics, commented: “We are pleased to see ivonescimab’s favourable intracranial response rates and median intracranial progression-free survival, as well as promising anti-tumour activity and safety profile in the subgroup of patients with brain metastases from NSCLC.
“We are grateful for the patients and clinical investigators supporting these trials, and our ongoing collaboration with our partners at Akeso.”
